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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idThe 2nd Scientiﬁc Advisory Board Meeting of the Global Center
for Mass Gathering Medicine, Ministry of Health, Riyadh, Kingdom
of Saudi Arabia, met April 28 – 29 in Riyadh to discuss risk of
infectious diseases and research and surveillance during Hajj. Due
to the on-going outbreak of MERS-CoV and especially the recent
increase in case detection in Jeddah, (138 MERS cases were
reported from Jeddah between 11 to 26 April 2014), the agenda for
the second day was focused on MERS-CoV, both in relation to the
risk it presents for the forthcoming Umrah during Ramadan and
the Hajj, but also in the Kingdom of Saudi Arabia and the Middle
East in general. The Ministry of Health used the opportunity to ask
the Scientiﬁc Advisory Board to review the MERS-CoV situation
globally with speciﬁc attention to MERS in the country and review
case deﬁnition, infection control guidelines and risk assessment to
nationals, residents, health care workers, family contacts, camel
owners, and travelers to KSA, and the future control.
1. Background
MERS-CoV is a new Coronavirus initially isolated from a patient
from Saudi Arabia in 2012.1 Phylogenetic analyses showed that the
virus was close to the SARS Coronavirus, and the epidemiology and
clinical presentation of infection with the two viruses has been
compared.2
As of May 1st 2014, the total number of laboratory conﬁrmed
MERS-CoV infections reported were 371, including 107 deaths.3
Countries in the Middle East reporting cases are KSA, Qatar, Jordan,
Oman, Kuwait and United Arab Emirates. Secondary cases has been
reported in several European (United Kingdom, France, Germany,
Italy, Greece), Asian (Malaysia and Phillipines) and Middle East
Area (MEA) (Egypt) countries, and the potential for a pandemic as
for SARS has been discussed.4,5, The cases outside the Arabian
peninsula and Middle East have either been infected in the Middle
East or been in close contact with a MERS-CoV cases. Only
secondary cases linked to index cases infected in the Middle East
have been reported and no further human to human transmission
has occurred. The US Centers for Diseases Control and Prevention
(CDC) announced on Friday May 2nd, 2014, the ﬁrst case of MERS-
CoV in a travelerto the United States from Riyadh, KSA.6
2. The Virus
Corona virus is found in all mammalian and avian species. The
origin of the MERS-CoV has been much discussed and bats werehttp://dx.doi.org/10.1016/j.ijid.2014.05.001
1201-9712/ 2014 Published by Elsevier Ltd on behalf of International Society for Infect
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and MERS-CoV.1 The phylogeny of Coronaviruses has been
extensively reviewed.7 Recently three entire MERS-CoV genomes
from Jeddah outbreak have been sequenced and the data was
presented at the Scientiﬁc Advisory Board Meeting of the WHO
Collaborating Center for Mass Gathering Medicine, Ministry of
Health, Riyadh, Kingdom of Saudi Arabia, April 28 – 29 (Drosten C
unpublished). The overall ﬁnding was announced the 26th April,8
and the conclusion is that overall the virus is stable and there is no
sign of mutations indicating an adaptation to cause sustained
human to human transmission.
3. Animal reservoirs
Dromedary camels have convincingly been shown to harbor the
virus and be able to shed MERS CoV in high numbers in secretions
from the upper respiratory tract.9 Studies of previous samples from
2005 found neutralizing antibodies to MERS-CoV in dromedars in
Dubai, indicating that the virus is not new on the Arabian
peninsula.10 It cannot be excluded that other animal reservoirs
exist, but the fact that the MERS-CoV cases primarily is reported
from the Middle East and in particular from the Arabian peninsula,
suggest that dromedars and camels in general are the main animal
reservoir and primary cases occur in areas where camels are an
important part of life. Unpasteurized camel milk is a possible route
of transmission, but so far there is no data on excreting of MERS-
CoV into camel milk.
4. Human transmission
The Scientiﬁc Advisory Board Meeting of the Global Center for
Mass Gatherings Medicine discussed the reported cases and the
risk factors for infection. The questions addressed were: 1) what
were the reasons for the increased case detection rates in March
and April as reported from Jeddah? 2) Was this due to seasonality
or increased virulence? 3) Had the human-to-human transmission
pattern changed and the basic reproductive rate increased? 4)
Were optimal infection control procedures followed? 5) Had the
clinical presentation of MERS-CoV changed? 6) What changes were
required in current recommendations for infection control
practices in the community or in hospitals? 7) What precautions
should those in contact with camels follow? 8) What advice should
be given to parents and schools? 9) What advice should be given to
travelers to the Middle East and should travel restrictions be inious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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What were the research priorities?
It is clear from previous reports that nosocomial infection is
important.11–14Household transmission is another important risk.15
5. Management of inpatients with MERS
Once in hospital with proved MERS-CoV treatment options are
limited and patients are most often in intensive care with
respiratory failure and may have multi-organ impairment
especially renal failure.16 It has been suggested looking at data
from SARS-CoV that Ribavirin and Interferon beta or lopinavir
combined with ritonavir may be used,17 but the experience so far is
limited.18 The use of hyperimmune plasma from patients
recovering from MERS-CoV may in theory also be an effective
treatment as has been shown for inﬂuenza.19
6. Conclusions
1. Sequencing of MERS-CoV isolates from Jeddah patients the
virus seems stable, showing no signs so far of mutations to
indicate an adaption to humans with increased risk of human
to human infections.
2. There is accumulating evidence for an animal reservoir in
dromedary camels. Transmission is thought to be due to close
physical contact or due to consumption of camel products.
3. The epidemiology since the virus was ﬁrst found in 2012 is
compatible with multiple introductions into humans from the
animal reservoir, with no long-term sustained human-to-
human transmission.
4. There is no human reservoir of cases with few or no symptoms.
5. The basic reproductive rate has been estimated to range below
1. Preliminary data from contact studies suggest a considerably
lower rate below 0.5, suggesting that the virus has no
pandemic potential. Special situations such as hospitalization
with breaches in infection control practice can however cause
local outbreaks with short transmission chains.
6. Nosocomial infection is an important risk factor for human to
human transmission. Thus infection prevention and control
measures are crucial to prevent the possible spread of MERS-CoV
within health care facilities. Hospital infection control proce-
dures needs to be emphazised and enforced. The Jeddah outbreak
showed that it is not always possible to identify patients with
MERS-CoV early because some have mild or unusual symptoms.
It is important that health-care workers apply standard
precautions consistently with all patients irrespective of the
diagnosis. Droplet precautions should be undertaken when
providing care to patients with symptoms of respiratory tract
infection. Contact precautions including eye protection should
be added when caring for suspected or conﬁrmed cases of MERS-
CoV infection. Airborne precautions should be taken when
performing aerosol generating procedures
7. In asymptomatic cases RT-PCR testing is not recommended.
Asymptomatic cases should be recorded and tested by serology
after 3 weeks from exposure, unless symptoms develop.
8. Awareness of MERS-CoV is important in countries where
camels and dromedars are a common livestock.
9. The importance of educational campaigns for educating health
care workers, the general public, family contacts and travelers
to the Middle East was emphasized. General hygiene measures
such as regular hand washing, antiseptic before and after
handling animals Owners of camels and dromedars should use
gloves and mask when handling ill animals.10. There is no evidence that camel’s milk tested positive for MERS,
however, milk has the potential of transmitting other
infections. Camel milk should be boiled before consumption.
Unpasteurised milk should not be consumed
11. There was no grounds for preventing children attending
schools and closing schools
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